J&J Sets The Pace In Race To $10bn RSV Vaccine Market

80% Efficacy Against Severe Disease In 65+ Group

 
• By Andrew McConaghie
  
Janssen Pharmaceutica sign and logo
GSK and Pfizer have already begun Phase III studies, but J&J's Phase II results are the most compelling so far.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip